Arterial and Venous Thromboembolism: Kinetic Characterization and Evaluation of Therapy

Laurence A Harker; Sherrill J Slichter

doi:10.1055/s-0038-1649157

Thrombosis and Haemostasis, Table of Contents

Thromb Haemost 1974; 31(02): 188-203
DOI: 10.1055/s-0038-1649157

Original Article

Schattauer GmbH

Arterial and Venous Thromboembolism: Kinetic Characterization and Evaluation of Therapy^[*]

Laurence A Harker

¹Department of Medicine, University of Washington School of Medicine, Harborview Medical Center and the King County Central Blood Bank Seattle, Washington 98104

,

Sherrill J Slichter

¹Department of Medicine, University of Washington School of Medicine, Harborview Medical Center and the King County Central Blood Bank Seattle, Washington 98104

› Author Affiliations

Abstract

Summary

Survival and turnover measurements of platelets, fibrinogen and plasminogen have been studied in eight patients with arterial and twelve patients with venous thromboembolism, and six patients with advanced, stable atherosclerotic peripheral vascular disease.

Venous thrombosis is characterized by combined and equivalent consumption of platelets, fibrinogen and plasminogen. This process, the result of activation of the coagulation system, is completely reversed by heparin or warfarin anticoagulation but remains unaltered by dipyridamole. The removal of circulating plasminogen is directly reflected as fibrinogen-fibrin related antigen in the blood and is regulated by the rate of fibrin formation as evidenced by the reversal of fibrinogen and plasminogen consumption to normal following heparin therapy.

In contrast, arterial thromboembolism involves selective platelet consumption presumably in the formation of platelet thrombus on non-endothelialized end-arterial surfaces. This process is interrupted by dipyridamole inhibition of platelet function but not by heparin anticoagulation. Although acetylsalicylic acid itself has little capacity to correct platelet consumption, it has a potentiating effect on dipyridamole.

Stable, severe, widespread arteriosclerotic disease only minimally increases platelet consumption and produces no change in fibrinogen and plasminogen kinetics from normal. The minimal decrease in platelet survival in these patients is not corrected by dipyridamole therapy.

The results of these studies demonstrate the potential usefulness of platelet and fibrinogen kinetic measurements in the differentiation of ongoing venous and arterial thromboembolism and in identifying potentially effective antithrombotic therapy.

Full Text

References

References
1 Abrahamsen A. F. Platelet survival studies in man: with special reference to thrombosis and atherosclerosis. Scandinavian Journal of Haematology (Supplement) 1968; 3: 1
2 Adelson E, Rheingold J. J, Parker O. et al. Platelet and fibrinogen survival in normal and abnormal states of coagulation. Blood 1961; 17: 267
3 Aster R. H. Effect of anticoagulant and ABO incompatibility on recovery of transfused human platelets. Blood 1965; 26: 732
4 Aster R. H. Pooling of platelets in the spleen: role in the pathogenesis of "hyper-splenic" thrombocytopenia. Journal of Clinical Investigation 1966; 45: 645
5 Bonchek L. I, Anderson B. P, Starr A. Mitral valve replacement with cloth-covered, composite seat prostheses : the case for early operation. Journal of Thoracic and Cardiovascular Surgery, (in press) 1973
6 Born G. V. B, Cross J. J. The aggregation of blood platelets. Journal of Physiology 1963; 168: 173
7 Bowie E. J. W, Owen Jr. C. A, Thompson J. H. et al. A test of platelet adhesiveness. Mayo Clinic Proceedings 1969; 44: 306
8 Browse N. L, Hall J. H. Effect of dipyridamole on the incidence of clinically detectable deep-vein thrombosis. Lancet 1969; 2: 718
9 Bull B. S, Schneiderman M. A, Brecher G. Platelet counts with the Coulter counter. American Journal of Clinical Pathology 1965; 44: 678
10 Deutsch D, Mertz E. T. Plasminogen: purification from human plasma by affinity chromatography. Science 1970; 170: 1095
11 Hardisty R. M, Hutton B. A. The kaolin clotting time of platelet-rich plasma: a test of platelet factor-3 availability. British Journal of Haematology 1965; 11: 258
12 Harker L. A, Finch C. A. Thrombokinetics in man. Journal of Clinical Investigation 1969; 48: 963
13 Harker L. A, Slichter S. J. Studies of platelet and fibrinogen kinetics in patients with prosthetic heart valves. New England Journal of Medicine 1970; 283: 1302
14 Harker L. A, Slichter S. J. Platelet and fibrinogen consumption in man. New England Journal of Medicine 1972; a 287: 999
15 Harker L. A, Slichter S. J. The bleeding time as a screening test for evaluation of platelet function. New England Journal of Medicine 1972; b 287: 155
16 Harker L. A, Schmer G, Slichter S. J. 1972. Plasminogen kinetics in man. In: Proceedings of the Third Congress of the International Society on Thrombosis and Haemostasis (abstract) 294
17 Harker L. A, Slichter S. J, Scott R. Platelet thromboembolism and its prevention in homocystinuria. Blood (abstract) 1972; 40: 938
18 Izak G, Galewski K, Eyal Z. Studies on hypercoagulable state II. The application of ¹³¹I-labelled fibrinogen for the estimation of intravascular coagulation in human subjects. Thrombosis et Diathesis Haemorrhagica 1967; 18: 544
19 Jacobsson K. 1955; Studies on the determination of fibrinogen in human blood plasma. Scandinavian Journal of Clinical Laboratory Investigation, 7 Supplement 14: 3
20 Johnson A. J, Kline D. L, Alkjaersig N. Assay methods and standard preparations for plasmin, plasminogen, and urokinase in purified systems. Thrombosis et Diathesis Haemorrhagica 1969; 21: 259
21 Kakkar V. V, Field E. S, Nicolaides A. N. Low doses of heparin in prevention of deep-vein thrombosis. Lancet 1970; 2: 669
22 McConahey P. J, Dixon F. J. A method of trace iodination of proteins for immunologic studies. International Archives of Allergy and Applied Immunology 1966; 29: 185
23 Merskey C, Lalezari P, Johnson A. J. A rapid, simple, sensitive method for measuring fibrinolytic split products in human serum. Proceedings of the Society of Experimental Biological Medicine 1969; 131: 871
24 Merskey C, Johnson A. J, Lalezari P. Increase in fibrinogen and fibrinrelated antigen in human serum due to in vitro lysis by thrombin. Journal of Clinical Investigation 1972; 51: 903
25 Mielke Jr. C. H, Kaneshiro M. M, Maher I. A. The standardized normal Ivy bleeding time and its prolongation by aspirin. Blood 1969; 34: 204
26 Mills J. N. The life-span of the erythrocyte. Journal of Physiology (London) 1946; 105: 16P
27 Murphy E. A, Mustard J. F. Coagulation tests and platelet economy in atherosclerotic and control subjects. Circulation 1962; 25: 114
28 Mustard J. F, Hegardt B, Rowsell H. C. et al. Effect of adenosine nucleotides on platelet aggregation and clotting time. Journal of Laboratory Clinical Medicine 1964; 64: 548
29 Paulus J. M. Platelet kinetics: Radioisotopic, cytological, mathematical and clinical aspects. New York: American Elsevier Publishing Co.; 1971
30 Schmer G, Kriss J. Solid phase radioassay for the measurement of plasminogen in normal human plasma. Journal of Laboratory Clinical Medicine 1973. (in press)
31 Sevitt S. Venous thrombosis and pulmonary embolism: their prevention by oral anticoagulants. American Journal of Medicine 1962; 33: 703
32 Sharnoff J. G. Results in the prophylaxis of postoperative thromboembolism. Surgery Gynecology Obstetrics 1966; 123: 303
33 Sherry S, Fletcher A. P, Alkjaersig N. Fibrinolysis and fibrinolytic activity in man. Physiology Review 1959; 39: 343
34 Slichter S. J, Leandoer J. L, Funk D. D, Harker L. A. Platelet and fibrinogen consumption with surgery. Clinical Research (abstract) 1971; 19: 431
35 Slichter S. J, Harker L. A. Studies of platelet and fibrinogen consumption in cancer patients. Clinical Research (abstract) 1972; 20: 194
36 Slichter S. J, Harker L. A, Sauvage L. R. Platelet consumption as a measure of endothelization of aorto-femoral grafts. Blood (abstract) 1972; 40: 938
37 Spaet T. H, Lejnieks I. A technique for estimation of platelet-collagen adhesion. Proceedings of the Society of Experimental Biological Medicine 1969; 132: 1038
38 Sullivan J. M, Harken D. E, Gorlin R. Pharmacologic control of thromboembolic complications of cardiac-valve replacement. New England Journal of Medicine 1971; 284: 1391
39 Takeda Y. Studies of the metabolism and distribution of fibrinogen in healthy men with autologous ¹²⁵I-labelled fibrinogen. Journal of Clinical Investigation 1966; 45: 103
40 Van der Maas A. P. C, Teulings F. A. G, den Ottolander G. J. H. The use of labelled fibrinogen in the diagnosis of venous thrombosis. Thrombosis et Diathesis Haemorrhagica 1971; 26: 1
41 Weiley H. S, Steele P. P, Davies H, Genton E. Platelet studies in patients with substitute heart valves. New England Journal of Medicine; 1973. (in press)
42 Weiss H. J, Aledort L. M, Kochwa S. The effect of salicylates on the hemostatic properties of platelets in man. Journal of Clinical Investigation 1968; 47: 2169

Arterial and Venous Thromboembolism: Kinetic Characterization and Evaluation of Therapy[*]

Arterial and Venous Thromboembolism: Kinetic Characterization and Evaluation of Therapy^[*]